908 Devices (NASDAQ:MASS) Stock Price Target Raised at Stifel Nicolaus

908 Devices (NASDAQ:MASS) had its price objective boosted by stock analysts at Stifel Nicolaus from $12.00 to $14.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective suggests a potential upside of 40.28% from the stock’s previous close.

Other analysts have also issued reports about the company. Roth Capital boosted their price objective on 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Canaccord Genuity Group initiated coverage on 908 Devices in a report on Thursday, September 10th. They issued a “buy” rating and a $13.50 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, November 4th. Finally, Wall Street Zen lowered 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.50.

908 Devices Price Performance

Shares of NASDAQ MASS opened at $9.98 on Wednesday. The stock has a market capitalization of $412.47 million, a P/E ratio of -10.51 and a beta of 0.66. The company has a 50-day moving average price of $11.19 and a 200-day moving average price of $8.51. 908 Devices has a 1 year low of $5.03 and a 1 year high of $13.35.

908 Devices (NASDAQ:MASS) last posted its earnings results on Tuesday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. The company had revenue of $18.95 million for the quarter, compared to analyst estimates of $18.31 million. As a group, equities research analysts anticipate that 908 Devices will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 11,459 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $10.95, for a total value of $125,476.05. Following the completion of the sale, the chief financial officer owned 121,497 shares in the company, valued at approximately $1,330,392.15. This trade represents a 8.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Brown sold 30,000 shares of 908 Devices stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $10.95, for a total transaction of $328,500.00. Following the transaction, the director directly owned 775,559 shares in the company, valued at approximately $8,492,371.05. This represents a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 134,115 shares of company stock worth $1,473,296. 28.20% of the stock is owned by insiders.

Institutional Trading of 908 Devices

Institutional investors and hedge funds have recently modified their holdings of the business. Pier 88 Investment Partners LLC lifted its holdings in 908 Devices by 59.2% during the third quarter. Pier 88 Investment Partners LLC now owns 22,600 shares of the company’s stock worth $279,000 after acquiring an additional 8,400 shares during the period. First Light Asset Management LLC increased its position in shares of 908 Devices by 3.5% during the 2nd quarter. First Light Asset Management LLC now owns 6,282,804 shares of the company’s stock valued at $54,660,000 after purchasing an additional 210,241 shares during the last quarter. Gainline Financial Partners LLC bought a new stake in shares of 908 Devices during the 2nd quarter worth $107,000. AXQ Capital LP bought a new stake in shares of 908 Devices during the 2nd quarter worth $93,000. Finally, Bank of America Corp DE purchased a new position in shares of 908 Devices in the 2nd quarter worth about $2,184,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Third-quarter revenue rose 35% year over year to a record $18.95 million, topping the $18.31 million consensus estimate. The company also reported record device shipments. 908 Devices Q3 2026 results
• Positive Sentiment: The quarterly loss of $0.11 per share was narrower than analysts’ expected $0.15 loss and the $0.15 loss reported a year earlier. Zacks earnings report
• Neutral Sentiment: 908 Devices forecast full-year 2026 revenue of $68.5 million to $70.0 million, close to the $69.1 million analyst consensus. The outlook therefore offered little apparent upside surprise.
• Negative Sentiment: The company continues to post substantial losses, including a negative net margin of 56.96%. Investors may be focused on the path to profitability despite the revenue and earnings-per-share beats.

908 Devices Company Profile

908 Devices Inc. is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions. The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.